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Abstract: Background & Aims: A single nucleotide polymorphism
61⁄G (rs4444903) in the epidermal growth factor (EGF) gene has
been associated, in two case–control studies, with hepatocellular
carcinoma (HCC). We tested associations between demographic, clin-
ical, and genetic data and development of HCC, and developed a sim-
ple predictive model in a cohort of patients with chronic hepatitis C
and advanced ﬁbrosis.
Methods: Black and white subjects from the Hepatitis C Antiviral
Long-term Treatment against Cirrhosis (HALT-C) trial (n = 816) were
followed up prospectively for development of a deﬁnite or presumed
case of HCC for a median time period of 6.1 years. We used the Cox
proportional hazards regression model to determine the hazard ratio
for risk of HCC and to develop prediction models.
Results: Subjects with EGF genotype G/G had a higher adjusted risk
for HCC than those with genotype A/A (hazard ratio, 2.10; 95% con-
ﬁdence interval, 1.05–4.23; P = .03). After adjusting for EGF geno-
type, blacks had no increased risk of HCC risk compared with
whites. Higher serum levels of EGF were observed among subjects
with at least one G allele (P = .08); the subset of subjects with EGF
G/G genotype and above-median serum levels of EGF had the highest
risk of HCC. We developed a simple prediction model that included
the EGF genotype to identify patients at low, intermediate, and high
risk for HCC; 6-year cumulative HCC incidences were 2.3%, 10.4%,
and 26%, respectively.
Conclusions: We associated the EGF genotype G/G with increased
risk for HCC; differences in its frequency among black and white sub-
jects might account for differences in HCC incidence between theseJournal of Hepatology 20
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In the current scenario of increasing costs for medical inter-
ventions, prevention and therapeutic algorithms need to be opti-
mized by the selection of ideal target patients. Efforts for
stratiﬁcation of patients with chronic liver disease by hepatocel-
lular carcinoma (HCC) risk using clinical and demographic vari-
ables have met with little success, not infrequently resulting in
the identiﬁcation of patients with excess risk of liver cancer, at
the same time leading to deferral of an unacceptable high num-
ber of individuals who still have a signiﬁcant residual risk of liver
cancer [1]. In principle, a clinical model incorporating a single
nucleotide polymorphism (SNP) for a potentially pathogenic
gene, like the Epidermal Growth Factor (EGF) gene, might
increase HCC prediction ﬁnalized to pretreatment stratiﬁcation
of patients with liver disease who are at risk of developing liver
cancer. The SNP involving an A to G transition at position 61 in
the 50 untranslated region of the EGF gene (SNP rs4444903),
which in vitro was associated with increased production of EGF
protein [2], has been the focus of investigations in patients with
chronic hepatitis. EGF is in fact recognized as an important driver
of the malignant transformation of different epithelial cells [3],
with some evidence that both EGF receptor and EGF signaling
could have a pathogenic role in HCC development [4,5].
Tanabe et al. [6] in two independent case–control study pop-
ulations in the USA (207 subjects with 59 HCC index cases) and in
France (141 subjects with 44 HCC index cases) provided a preli-
minary evidence that genotyping for EGF polymorphism coupled
with assessment of serum levels of EGF protein, may serve as
novel markers of HCC risk in patients with cirrhosis of mixed eti-
ology. The working hypothesis of this retrospective study was
that EGF SNP modulates EGF mRNA half-life to the point of
increasing the stability of EGF transcripts in human hepatoma cell
lines carrying the G allele, thereby resulting in an increased
in vitro expression of EGF protein in G/G compared to A/A cell
lines that in vivo translated in greater accumulation of serum
and liver EGF protein in the former patients (Fig. 1). These scien-
tiﬁcally attractive ﬁndings provided a strong rationale to validate
EGF SNP as a predictor of HCC in a set of prospectively recruited
patients with advanced liver ﬁbrosis who were framed into the12 vol. 56 j 1415–1416
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Fig. 1. Proposed mechanism for EGF polymorphism. ⁄Data from Tanabe et al.
[6].
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lated interferon [7]. Patients carrying the genotype GG represent-
ing the 25% of the overall population of patients, showed a
moderate (2-fold) cumulative risk of developing a HCC during a
follow-up period of 6 years compared to patients with genotype
AA, comprising 29% of the study cohort. When EGF polymorphism
was associated with demographic and clinical predictors of HCC
like age, gender, smoking, alkaline phosphatase and platelet
count that were identiﬁed by univariate analysis, 14% of the
patients were in the high score setting with a 26% cumulative
rate of developing HCC in 6 years compared to 29% who were
in the intermediate score setting with a HCC rate of 10.4% and
57% of the study population who were in the low score setting
with a HCC rate of 2.3%, only. While at ﬁrst glance these results
are clinically attractive with respect to improving pretreatment
stratiﬁcation of patients with chronic hepatitis C, several aspects
of the study question the interpretation and clinical applicability
of the new score system. The HALT C cohort, in fact, is far from
being a representative population to study HCC predictors, as it
misses numerous HCC risk patients who were deferred from
treatment because of intolerance or contraindications to inter-
feron-based therapies or successfully responded to therapy. We
should not forget that in the USA at the time of the conduct of
HALT-C trial, 64% of the adult infected population did not meet
the eligibility criteria for interferon therapy, and was therefore
deferred, whereas 11.6% ultimately received pegylated interferon
and ribavirin therapy, only [8]. Another potential source of bias in
Dr. Abu Dayyeh report was the signiﬁcant number (236 of 1050)
of patients who did not consent or could not be recruited to
genetic testing, not to mention the contradictory ﬁndings of the1416 Journal of Hepatology 2012extended follow-up of the HALT C study. At year 6 of follow-up,
less cirrhotics and patients with 62 point decline of Knodell score
following 3.5 years of weekly treatment with 90 lg pegylated
interferon a2a developed a HCC compared to non-cirrhotics
and those with unchanged or increased scores of liver inﬂamma-
tion [9]. On the other hand, mortality rates from liver unrelated
causes were signiﬁcantly increased among all interferon-treated
patients [10]. All in all, these discrepancies highlight the need
to externally validate the EGF SNP-based score in an appropriate
setting of patients and to investigate patients with other than
hepatitis C liver disease, as easily accessible genetic predictors
of HCC look instrumental to optimize current algorithms of pri-
mary and secondary prevention of liver cancer.Conﬂict of interest
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